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Background.ForM1pancreaticadenocarcinomaspancreaticresectionisusuallynotindicated.However,inhighlyselectedpatients
synchronous metastasectomy may be appropriate together with pancreatic resection when operative morbidity is low. Materials
and Methods. From January 1, 2004 to December, 2007 a total of 20 patients with pancreatic malignancies were retrospectively
evaluated who underwent pancreatic surgery with synchronous resection of hepatic, adjacent organ, or peritoneal metastases for
provenUICCstageIVperiampullarycancerofthepancreas.Perioperativeaswellasclinicopathologicalparameterswereevaluated.
Results. There were 20 patients (9 men, 11 women; mean age 58 years) identiﬁed. The primary tumor was located in the pancreatic
head (n = 9, 45%), in pancreatic tail (n = 9, 45%), and in the papilla Vateri (n = 2, 10%). Metastases were located in the liver
(n = 14, 70%), peritoneum (n = 5, 25%), and omentum majus (n = 2, 10%). Lymphnode metastases were present in 16 patients
(80%). All patients received resection of their tumors together with metastasectomy. Pylorus preserving duodenopancreatectomy
was performed in 8 patients, distal pancreatectomy in 8, duodenopancreatectomy in 2, and total pancreatectomy in 2. Morbidity
was 45% and there was no perioperative mortality. Median postoperative survival was 10.7 months (2.6–37.7months) which was
not signiﬁcantly diﬀerent from a matched-pair group of patients who underwent pancreatic resection for UICC adenocarcinoma
of the pancreas (median survival 15.6months; P = .1). Conclusion. Pancreatic resection for M1 periampullary cancer of the
pancreas can be performed safely in well-selected patients. However, indication for surgery has to be made on an individual
basis.
1.Introduction
Surgery for pancreatic cancer is probably the most demand-
ing and risky operative procedure in abdominal surgery
[1]. Remarkable progress has been achieved during the
last three decades and pancreatic surgery can nowadays
be performed safely with low morbidity and mortality in
variousspecializedhospitalsaroundtheworld.Thisisinpart
a result of regionalization of pancreatic surgery into high
volume centers [2] resulting in an increased resection rate
in the presence of pancreatic carcinoma which is nowadays
approximately 60% and to an extension of indications
for resection. Consequently, vascular resection, considered
a contraindication for pancreatic resection a couple of
years ago, is now implemented in the armamentarium of
pancreatic surgeons to realize R0-resections when clearance
of the portal or superior mesenteric vein can not be realized
without vascular resection.
The results following synchronous resection of liver
metastasis together with resection of periampullary or pan-
creatic adenocarcinoma or pancreatic resection for M1 car-
cinoma are not equivocal. Although these procedures can be2 HPB Surgery
performed safely, the median survival time ranges between
6 and 13 months [3, 4]. Therefore, synchronous metasta-
sectomy of periampullary cancer is rarely performed when
extended disease has already been found preoperatively.
However, within daily clinical practice diﬀerent scenarios
occur which may require a decision for resection in an M1
situation.Inayoungpatientwithadvanceddisease,resection
may provide a small but important increase of survival. In
addition, metastatic disease may become overt when the
point of no return has already been passed as it may be the
case in the presence of positive interaortocaval lymphnodes,
or metastatic disease will be detected during operation
despite negative imaging results preoperatively. Finally, a
strong patient desire may force the surgeon to go further
than consented guidelines may summarize existing evidence.
Since curative R0 resection is the most important prognostic
factorforlong-termsurvivalevenasmallpotentialtoachieve
R0 resection may provide the legitimisation for extended
resectiondespitethefactthatovertsystemicdiseaseisalready
present.
So far, there is little data available on the value of syn-
chronous metastasectomy together with pancreatic resection
in patients with pancreatic carcinoma. Patients who undergo
resection of metastases together with pancreatic resection
seem to have a higher complication rate than patients
with multivisceral liver resections [5]. An extended lym-
phadenectomy is associated with an increased postoperative
complication rate, but has no impact on long-term survival
[6].
The fact that despite R0 resection long-term survival
doesnotexceed25%eveninthemostexperiencedpancreatic
centers may prove that carcinoma of the pancreas is a
systemic disease. Further improvement of survival can
only be achieved by adjuvant treatment [7] (Picozzi et al.,
2003). It seems logical, that in the presence of metastatic
diseasealowtumorloadmayincreasethesuccessofadjuvant
chemotherapy although the absolute increase in survival
time may be very low. We therefore hypothesized that radical
resection of M1-pancreatic carcinoma may be justiﬁed in
well-selected patients as long as these operations can be
performed with a low morbidity and mortality.
Thus, we aimed at reviewing our experiences with pan-
creatic resections in patients with M1 periampullary cancer
of the pancreas after having launched a new pancreatic
program in our hospital.
2. Patientsand Methods
Between January 2004 and December 2007, 470 patients
underwent surgery for pancreatic cancer. There were 280
patients who underwent either pancreatoduodenectomy
or left-sided pancreatic resection for histologically proven
pancreaticadenocarcinomaorperiampullarycancer.Among
this patient population we identiﬁed 20 (7,1%) patients (9
men, 11 women; mean age 60 years) in our prospective
database who underwent either a pancreaticoduodenec-
tomy (PD), or a left-sided distal pancreatectomy together
with resection of metastasis for pancreatic adenocarcinoma.
Resection of metastatic disease was deﬁned as the resection
of any tumor deposit outside the regional lymph nodes
or resection of inﬁltrated surrounding organs in order
to achieve a R0 resection. Patients with neuroendocrine
tumors or metastatic disease into the pancreas were not
considered.
Perioperative imaging included a computed tomography
scanning and endoscopic ultrasound in all instances. Mag-
netic resonance imaging, magnetic resonance cholangiog-
raphy, or endoscopic retrograde cholangiopancreatography
were performed when indicated.
In patients who were found intraoperatively to harbour
metastatic disease the decision for resection was based on
the impression to reach a R0 situation with synchronous
resection of metastasis and a good clinical performance
status of ASA III or better. Patients with suspected metastatic
disease preoperatively were operated with potentially cura-
tive intention or with palliative intention. Reasons for
resection were good performance status and patient’s will to
receive maximal treatment.
All pathologic specimen were reviewed by a single pa-
thologist (AT) to conﬁrm the diagnosis of pancreatic adeno-
carcinoma or cancer of the papilla Vateri.
The overall incidence of postoperative complications was
evaluated. A pancreatic ﬁstula was deﬁned as a prolonged
drainage with amylase activity of more than 10.000U/L.
Wound infection was deﬁned as any wound requiring
reopening for the drainage of pus together with a positive
wound culture. Mortality was deﬁned as any death during
postoperative hospitalization or within 30 days of surgery.
Follow-up information was obtained through direct contact
with the patient and review of hospital charts and opera-
tive notes. Follow-up data was complete for every patient
(100%).
The results of the study group were compared with a
matched-pair control group of 20 patients with pancreatic
adenocarcinoma, who were matched according to age and
tumor location and who did undergo only pancreaticoduo-
denectomy or distal pancreatic resection for stadium IIb or
III pancreatic adenocarcinoma.
2.1. Statistical Analysis. All statistical analyses were per-
formed using SPSS-software (version 15). The distribution
of age at operation, blood loss, and postoperative hospital
stay were presented as median with range. Comparisons
between subgroups were performed with Fisher’s exact test
and diﬀerences between means were tested by the t-test.
Cases were matched with control group (resection without
multivisceral resection) in a 1:1 fashion. Speciﬁcally, cases
and controls were matched on primary tumor characteristics
and age of the patient. Morbidity, mortality, and overall
survival were compared between cases and control group.
The nonparametric product limit method (Kaplan-Meier
estimations) was used to analyse overall survival from the
date of surgery. Diﬀerences in survival were examined using
the log-rank test. Two-sided P values were always computed
and an eﬀect was considered statistically signiﬁcant at
P ≤ .05.HPB Surgery 3
Table 1: Clinicopathologic characteristics (M1-Patients).
Variable No. of patients (%) (n = 20)
Patient characteristics
Mean age ± SD 58.4 ± 11.8
Sex (% men) 9 (45)
Median tumor size (cm) 4.1 (1–11)
Lymph node disease 16 (80)
Origin of tumor
Pancreas head 9 (45)
Pancreas corpus/tail 9 (45)
Papilla 2 (10)
Hepatic metastasis 14 (70)
Preoperative known 9 (45)
unknown 5 (25)
Median size of largest metastasis (cm) 1,6 (0,5–4,0)
Solitary metastases 5 (25)
Other metastases
Peritoneum 5 (25)
Omentum majus 2 (10)
Lymphnodes 4 (20)
Adjuvant chemotherapy 20 (100%)
(+neoadjuvant chemotherapy) 2 (10)
Median survival (months) 10.7 (2.6–37.8)
2.2. Results
2.2.1. Patient Data. The primary tumor was located in the
pancreatic head in 9 (45%) patients, in the pancreatic tail in
9 (45%), and at the papilla Vateri in 2 (10%). Synchronous
liver metastasis was present in 14 (70%) patients, 4 (20%)
patients had peritoneal metastases, one patient had a metas-
tasis in the transverse mesocolon, 2 (10%) patients had a
metastasisinthegreateromentum,and3(15%) patientshad
macroscopically lymph node metastases. Six patients (30%)
had metastatic disease at more than one location. In 7 (35%)
patients the tumor was locally advanced with inﬁltration of
stomach or pylorus. Metastatic disease was known before
operation based on preoperative imaging in 5 of 20 patients
(25%).
Details of the patients are given in Table 1.
2.2.2. Operations. Of the 20 patients, 8 (40%) underwent
a pylorus-preserving duodenopancreatectomy and 2 (10%)
a classic Whipple-procedure. In 8 (40%) patients a distal
pancreatic resection was performed and 2 (10%) patients
underwent a total pancreatectomy.
Details of the localisation of the tumor and the metas-
tases, TNM-staging, R-status postoperatively, and type of
surgery performed are listed in Table 2.
An R0/R1-resection could be achieved in 11 patients
(55%), whereas in the remaining patients only an R2 resec-
tion was performed due to remaining metastatic disease in
liver.
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Figure 1: Kaplan-Meier curve comparing survival curve of patients
with metastases and patients who did not have metastases (P = .11;
log-rank test).
2.2.3. Perioperative Data. There was no perioperative mor-
tality, and complications occurred in 9 (45%) patients.
The median intraoperative blood loss was 1000mL (range
300–2500mL) and the median postoperative length of
hospital stay was 20.7d (11–71d). This was statistically
not diﬀerent to a matched-pair group of patients with
ductal adenocarcinoma of the pancreas without metastatic
disease (Tables 3 and 4). All patients received postoperative
adjuvant or palliative chemotherapy, two patients underwent
neoadjuvant radiochemotherapy prior to surgery.
2.2.4. Survival. The median postoperative survival was 10.7
months (range 2.6–37.8mo) which was not signiﬁcantly
diﬀerent to the control group who had a median survival
time of 15.6 months (P = .11; Figure 1). All deaths were
caused by recurrent cancer. There was no diﬀerence in
the median survival between patients with liver metastases
(median survival time 11 months) compared to patients
who had metastases at other locations (median survival 14.1
months; P = .62).
3. Discussion
Pancreatic cancer still carries a dismal prognosis and the
potential to cure a patient can only be achieved when
the primary tumor can be completely resected. However,
this scenario can only be accomplished in about 5%–
25% of patients presenting with locally resectable cancer.
Patients with metastatic pancreatic cancer who receive
palliative chemotherapy with gemcitabine have a median
survival time of 5.6 months [8]. Various protocols with4 HPB Surgery
Table 2: Localisation of primary tumor, site of metastasis, TNM-staging, type of surgery, and survival of 20 patients with M1-pancreatic
adenocarcinoma.
No. Primary tumor Site of metastasis TNM R Type of surgery Survival (mo) Status
1 Pancreatic tail Liver segment 5 and 6,
peritoneum T3N0M1 R2 Distal pancreatectomy, tumor
debulking 5.3 Dead
2 Pancreatic head
Liver (multifocal),
peritoneum, mesocolon
transversum
T3N1M1 R2 pp-Whipple 21.3 Dead
3 Pancreatic body
Liver segment 2/3,
peritoneum, stomach,
mesocolon transversum,
diaphragm
T3N1M1 R0
Distal pancreatic resection,
gastrectomy, left hemicolectomy,
liver segment 2/3
2.6 Dead
4 Pancreatic head Liver segment 2/3,
peritoneum T3N1M1 R2 Whipple procedure, gastrectomy,
right hemicolectomy 15.2 Dead
5 Pancreatic head Liver segment 3 T3N1M1 R0 pp-Whipple, atyp. liver segment 3 9.3 Dead
6 Pancreatic tail
Peritoneum, ovary,
inﬁltration of stomach,
colon transversum and left
kidney
T4N1M1 R2
Distal pancreatectomy, 2/3 gastric
resection, left hemicolectomy, left
nephrectomy, left adrenalectomy
5.1 Dead
7 Pancreatic body
Liver segment 3,5,
inﬁltration of stomach and
celiac trunk
T3N1M1 R0
Distal pancreatectomy, subtotal
gastric resection, liver resection seg.
3+5
10.6 Dead
8 Pancreatic head Omentum majus T3N0M1 R0 Whipple-procedure, partial portal
vein resection, omentectomy 20.6 Dead
9 Pancreatic head Liver segment 4b T3N1M1 R0 pp-Whipple, liver segment 4b 37.8 Alive
10 Pancreatic body
Liver segment 3, 4b, 5,
peritoneum, portal vein
and pylorus inﬁltration
T3N1M1 R1
Pancreatectomy, 2/3 gastric
resection, atypical liver resection,
partial portal vein resection
10.6 Dead
11 Pancreatic head Liver segment 2, 3, 4 T3N1M1 R2 pp-Whipple, Biopsy segment 3 6.8 Dead
12 Pancreatic body Liver bilobar T3N1M1 R2 Distal pancreatic resection, liver
segment 3 and 7 23.7 Alive
13 Pancreatic head Liver segment 3 T3N1M1 R0 pp-Whipple, atypical liver segment
3 11 Dead
14 Papilla Diﬀuse lymph node
metastases T3N1M1 R0 pp-Whipple, lymph node resection 18,2 Dead
15 Pancreatic tail Stomach inﬁltration T3N0M1 R0 Distal pancreatic resection, gastric
resection 25.6 Dead
16 Pancreatic tail Liver bilobar, Stomach
inﬁltration T3N0M1 R2 Distal pancreatic resection, gastric
resection 14.3 Alive
17 Pancreatic head Liver segment 4 a + b T3N1M1 R0 pp-Whipple, atypical liver resection 12.5
18 Pancreatic tail
Liver segment 5 + 8,
metastasis stomach,
inﬁltration of left adrenal
and splenic artery
T3N1M1 R2 Distal pancreatic resection, left
adrenalectomy, gastric resection 10.5 Dead
19 Pancreatic head Inﬁltration of stomach and
portal vein T3N1M1 R0 Pancreatectomy, 2/3-gastric
resection, portal vein resection 14.1 Dead
20 Papilla Liver segment 3 + 4a T4N1M1 R2 pp-Whipple, liver segment 3, 4a 8 Dead
(1) pp-Whipple: pylorus-preserving pancreaticoduodenectomy.
gemcitabine-based regimen or multidrug regimen tested
in prospectively randomised phase III clinical trials have
not altered this situation substantially making metastatic
pancreatic cancer one of the most frustrating malignancies
to investigate and treat [9]. Therefore, when metastatic
disease is recognized preoperatively, an operative procedure
is usually avoided except for surgical palliation. In addition,
accordingtotheS-3guidelinesoftheGermanCancerSociety
pancreatic resections should be avoided in the presence of
intraoperative metastatic disease [10]. However, locally
advanced disease may be resected as long as an R0 resection
can be achieved. Both statements have a grade of evidence of
3 which means that only systematic reviews and individual
case control studies are available to scientiﬁcally support
this statement. It seems reasonable, that postoperative
c h e m o t h e r a p ym a yb em o r ee ﬀective, when no gross tumorHPB Surgery 5
Table 3: Patient’s clinicopathologic characteristics (M0-Patients).
Variable No. of patient (%), n = 20
Patient characteristics
Mean age ± SD 62.3 ± 12
S e x( %m e n ) 1 1( 5 5 )
Median tumor size (cm) 3.9 (1.3–7)
Lymph node disease 16 (80)
Origin of tumor
Pancreas head 9 (45)
Pancreas corpus/tail 9 (45)
Papilla 2 (10)
Adjuvant chemotherapy 20 (100%)
Median survival (months) 15.6 (5.3–35.9)
Table 4:Operativedetailsofstudygroup(M1-Patients)andcontrol
group (M0).
M1 M0 P-
value
Intraoperative blood loss
(mL)
1000
(300–2500)
1400
(500–5100) .32
Main operative procedure
Pylorus preserving
Whipple 8 (40) 7
Whipple 2 (10) 5
Distal pancreatectomy 8 (40) 6
Pancreatectomy 2 (2) 2
Length of postoperative
hospital stay (days) 20.7 (11–71) 25.1 (12–92) .46
Complications 9 (45) 10 (50) .76
is left in situ. In addition, the high recurrence rate even after
R0 resection is an indirect prove for early systemic spread
which is not treatable by surgery but by chemotherapy.
This demonstrates that additional data is required to
solve this issue. Our study gives support to the hypothesis—
despite the relatively small number of patients—that in
the presence of metastasis of a pancreatic adenocarcinoma
radical resection is possible and safe and that overall survival
is comparable to patients who do not have metastatic
disease. This relatively good result is in part consequence of
restriction of the procedure to well suited patients who were
expected to tolerate even a signiﬁcantly expanded procedure.
The mean age of our patients was 58 years, and all patients
were either ASA 1 or 2 (data not given). Therefore, it
was expected that these patients would tolerate pancreatic
resection with synchronous metastasectomy without signif-
icant increase in morbidity or mortality. In addition, every
patientreceivedchemotherapypostoperatively.Nevertheless,
themediansurvivalof10.6monthsislow,butwebelievethat
we could oﬀer these patients additional life time, although
quality of life was not evaluated. However, these procedures
should be restricted to well-suited patients and only be
performed at centers with signiﬁcant expertise in pancreatic
surgery.
A shortcoming of the study may be the fact that patients
had various presentation of the M1 category. Most of our
patientshadlivermetastasis,buttherewerealsopatientswith
peritoneal or lymph nodes metastases who were classiﬁed as
M1 or the tumor involved surrounding organs. Since there is
no signiﬁcant diﬀerence in survival according to the location
of the metastasis of pancreatic carcinoma, we believe that an
analysis of this group was appropriate.
According to the results of at least 3 randomized
trials extended lymphadenectomy has not been eﬀective in
improving survival of patients with pancreatic adenocarci-
noma with 1 and 3 years survival between 51% and 77%
and between 16 and 41%, respectively [6]. Therefore, in
an nonmetastasized pancreatic adenocarcinoma a standard
lymphadenectomy is adequate.
When locally advanced cancer with suspected venous
inﬁltration is present extensive surgery can be performed
safely with morbidity and mortality rates comparable to
conventional resections. In a recent analysis of 136 patients
with locally advanced pancreatic cancer Yekebas et al.
could demonstrate that patients with concomitant vascular
resections had the same median (15 versus 16mo; P = .86)
and two year survival (34% versus 36%: P = .9) compared to
patientswhodidnotundergovascularresection[11].Evenin
multivariate analysis vascular inﬁltration was not considered
a negative prognostic factor. Even arterial encasement of
the celiac trunk in the presence of a pancreatic corpus
carcinoma is not considered a contraindication for surgery.
Hirano et al. recently published a series of 23 patients with
pancreatic body cancer with inﬁltration of the celiac trunk.
Negative surgical margins were obtained in 91% of patients,
postoperative mortality was 0%, and the median survival
was 21 months [12]. However, early hepatic recurrence in 6
patients was a hint that this procedure may be indicated for
the treatment of less advanced disease.
In a recently published study Shrikhande et al. reported
a series of 29 patients with M1 ductal adenocarcinoma
of the pancreas who underwent pancreatic resection with
synchronous resection of metastases. Of these 11 patients
had metastatic disease to the liver and 9 to the peritoneum.
The median survival following resection was 11.4 months
and 12.9 months, respectively [4]. The authors concluded,
that concomitant resection of primary pancreatic tumor and
metastases can be performed safely. However, a risk beneﬁt
ratio should be carefully assessed since the overall increase
in survival is moderate. In our study the survival time of
patients with liver metastasis was 11 months compared to
14.1 months when metastases were located at other regions
(P = .62). These values are comparable to the values
published by Shrikhande et al. [4].
In a study of 22 patients who underwent pancreatic
resection and synchronous liver resection for metastasised
pancreatic adenocarcinoma, Gleisner et al. found that the
median survival was only 5.9 months, which was not
statistically diﬀerent from patients who underwent palliative
bypass alone (5.6 months; P = .46) [3]. They concluded
from the results of their study that simultaneous resection
for patients who present with synchronous liver metastasis
from pancreatic adenocarcinoma is not justiﬁed. In our6 HPB Surgery
study we found a median survival of 10.6 months for the
complete group, while the 14 patients with liver metastases
had a median survival of 11 months. Despite this small
increase we believe that in highly selected patients after
careful counselling this aggressive therapy is still an option
that should be oﬀered to the patient.
The fact that there was no signiﬁcant diﬀerence in
survival between the study and the matched-pair control
group despite an objective diﬀerence in the median survival
of 5 months is probably due to the limited number of
patients. With an increased number of patients we would
have expect this diﬀerence to reach statistical signiﬁcance.
Compared to published results of patients receiving pal-
liative chemotherapy who have a median survival time of
approximately 5.4–8.4 months [13, 14], the increase in
survival in patients with M1 ductal adenocarcinoma of
the pancreas is about 2-5 months. This increase is not
substantial to recommend this procedure in general. We
believe that patients who may beneﬁt must be carefully
selected and therapeutic options and expected survival
should be discussed with the patients and their families. In
addition, the perioperative morbidity and mortality must be
low.
Inthepresenceofpancreaticneuroendocrinecarcinomas
extended resections or even debulking operations seem to be
associated with increased survival. Sarmiento et al. reported
onaseriesof23patientswithpancreaticislet-cellcarcinomas
with synchronous hepatic metastases who underwent syn-
chronous hepatic resections without perioperative mortality.
9 patients were resected R0/R1 and 14 had a R2-resection.
The overall survival was 71% with a median survival time of
76 months [15]. This demonstrates, that extended resections
in this subset of metastasized patients with primary pancre-
atic tumors are justiﬁed. The preoperative or intraoperative
diﬀerentiation between a pancreatic adenocarcinoma and
a neuroendocrine carcinoma may be diﬃcult when typical
carcinoma associated syndromes are missing preoperatively.
However, intraoperatively the diﬀerentiation may be easier
from the macroscopic point of view, and when histology has
not been determined preoperatively, intraoperative frozen
section may identify the tumor so operative strategy can be
planned appropriately.
Currently, a monocentric prospective randomized trial
on the value of pancreatic resection in the presence of
liver metastasis is under way in Germany (NCT00855634,
PAMEVITUM). The results of this study may give further
evidence whether pancreatic resection in this scenario is
justiﬁed.
The results of our study demonstrate, that resection
of pancreatic adenocarcinoma with synchronous metastases
can be performed safely. Justiﬁcation for combined resection
should be made on an individual basis for each patient only.
There is probably a small increase in survival compared to
patients who undergo palliative chemotherapy and there was
no statistically signiﬁcant diﬀerence in survival compared
to patients who underwent resection for stadium IIb or III
tumors. The decision to resect a patient in an M1 situation
should be carefully assessed and may be an option in highly
selected cases.
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